Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REKLAIM: FBX-101 in Krabbe Disease Post-HSCT
NCT05739643Phase 2Active, not recruiting
- Sponsor
- Duke University
- Start
- Feb 2023
- Primary completion
- Jun 2028
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 1
01
Overview
A Phase 2 trial of FBX-101 in Krabbe disease, sponsored by Duke University. Started Feb 2023; status: active, not recruiting.
02
Drugs
FBX-101
03
Conditions
Krabbe disease
Beyond the preview
Go deeper on NCT05739643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05739643.